Citigroup Inc. Sells 29,416 Shares of Tenet Healthcare Corporation $THC

Citigroup Inc. trimmed its holdings in shares of Tenet Healthcare Corporation (NYSE:THC) by 7.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 369,555 shares of the company’s stock after selling 29,416 shares during the quarter. Citigroup Inc. owned about 0.42% of Tenet Healthcare worth $75,034,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently modified their holdings of THC. Boston Partners increased its position in shares of Tenet Healthcare by 95.0% in the second quarter. Boston Partners now owns 2,267,142 shares of the company’s stock worth $398,949,000 after purchasing an additional 1,104,500 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Tenet Healthcare by 8.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,119,423 shares of the company’s stock worth $373,020,000 after buying an additional 157,109 shares during the last quarter. Norges Bank purchased a new stake in shares of Tenet Healthcare during the 2nd quarter valued at $206,981,000. AQR Capital Management LLC grew its position in Tenet Healthcare by 28.0% in the second quarter. AQR Capital Management LLC now owns 1,156,263 shares of the company’s stock worth $200,224,000 after acquiring an additional 252,993 shares in the last quarter. Finally, Alliancebernstein L.P. raised its position in Tenet Healthcare by 375.7% during the second quarter. Alliancebernstein L.P. now owns 790,254 shares of the company’s stock valued at $139,085,000 after purchasing an additional 624,125 shares in the last quarter. Institutional investors own 95.44% of the company’s stock.

Tenet Healthcare Stock Performance

Shares of NYSE:THC opened at $229.56 on Monday. The company has a current ratio of 1.76, a quick ratio of 1.68 and a debt-to-equity ratio of 2.18. The company has a market cap of $19.96 billion, a price-to-earnings ratio of 14.82, a price-to-earnings-growth ratio of 1.13 and a beta of 1.45. Tenet Healthcare Corporation has a 12 month low of $109.82 and a 12 month high of $235.77. The company has a 50-day moving average price of $201.87 and a 200-day moving average price of $197.69.

Tenet Healthcare (NYSE:THC) last released its quarterly earnings results on Wednesday, February 11th. The company reported $4.70 EPS for the quarter, beating analysts’ consensus estimates of $4.08 by $0.62. The business had revenue of $5.53 billion during the quarter, compared to analyst estimates of $5.47 billion. Tenet Healthcare had a return on equity of 26.33% and a net margin of 6.60%.Tenet Healthcare’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.44 EPS. Tenet Healthcare has set its FY 2026 guidance at 16.190-18.470 EPS. As a group, equities analysts anticipate that Tenet Healthcare Corporation will post 12.24 EPS for the current year.

Insider Transactions at Tenet Healthcare

In other Tenet Healthcare news, Director Nadja West sold 2,178 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $197.47, for a total transaction of $430,089.66. Following the transaction, the director directly owned 28,480 shares of the company’s stock, valued at approximately $5,623,945.60. The trade was a 7.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.81% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on THC. Morgan Stanley reiterated an “overweight” rating and set a $260.00 price objective on shares of Tenet Healthcare in a research report on Thursday, February 12th. TD Cowen reissued a “buy” rating on shares of Tenet Healthcare in a research note on Thursday, February 12th. KeyCorp upped their price objective on shares of Tenet Healthcare from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Thursday, February 12th. JPMorgan Chase & Co. lifted their target price on shares of Tenet Healthcare from $200.00 to $230.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Finally, Guggenheim raised their price objective on Tenet Healthcare from $257.00 to $271.00 and gave the company a “buy” rating in a research note on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Tenet Healthcare presently has an average rating of “Moderate Buy” and an average target price of $247.67.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.